Clinical trial · Observational
Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
NCT02065297CI-TRIAL-00038459completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this open, controlled, multicentre biomedical research study is to identify new markers specifically associated with Horton's disease. This would make it possible to improve the diagnosis and management of this disease. Participation consists in taking one or several blood samples depending on the group patients/controls.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hemopathy | — | UNRESOLVED | — |
| Horton's Disease | — | UNRESOLVED | — |
| Infectious Disease | — | UNRESOLVED | — |
| Neoplasia | Neoplasm | ALIAS | 0.90 |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1 blood sample | Other | — | UNRESOLVED |
| 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Horton's disease
- interventionNames
- Other: 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)
- label
- Infectious disease
- interventionNames
- Other: 1 blood sample
- label
- Neoplasia
- interventionNames
- Other: 1 blood sample
- label
- Control
- interventionNames
- Other: 1 blood sample
Primary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: Patients * Patients who have provided written informed consent * Patients with national health insurance cover * Age: 50 to 90 years Patients with Horton' s disease : * at the diagnosis, before any treatment * or in remission * or in relapse Patients with an infectious disease : * Bacteriologically or radiologically confirmed * Presenting an inflammatory syndrome defined by : * CRP ≥ 10 mg / L * and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1 Patients with neoplasia ( solid tumour or hemopathy ) : * At the diagnosis, before treatment by chemotherapy * Presenting an inflammatory syndrome defined by: * CRP ≥ 10 mg / L * and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1 Controls : These are healthy volunteers recruited among blood donators at Dijon CHU, voluntary hospital personnel ( nurses, doctors and secretaries ), patients at the EPHAD ( Champmaillot centre for geriatric patients ) and patients without infectious, inflammatory, or auto-immune disease ( CRP \< 5mg / L ) or cancer recruited from the investigating departments of Dijon CHU. They will be matched for age and sex. * Age: 18 - 90 years * Patients with national health insurance cover * who have provided written informed consent * Absence of an inflammatory syndrome ( CRP \< 5 mg / L ) Exclusion Criteria : * Any patient who does not meet the inclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.